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Abstract: One less visited area in musculoskeletal stem cell research is the effects of donor age on quality of stem cells. 
The prevalence of degenerative orthopaedic conditions is large, and the older population is likely to receive great benefit 
from stem cell therapies. There are many known growth factors involved in controlling and influencing stem cell growth 
which are also related to cell senescence. Of which, expressions are found to be altered in mesenchymal stem cells from 
older donors. Considerations must also be taken of these mechanisms which also have a role in cell cycle and tumour 
suppression. 
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  Degenerative and many other orthopaedic conditions 
widely affect the older population. There is a lot of active 
mesenchymal research in the orthopaedic field looking for 
ways to combat these diseases. So this review looks at the 
implications of ageing with regards to mesenchymal stem 
cells and the impact it has on replication for these cells. In 
vivo work and the concept of replicative senescence in vitro 
and techniques researchers are discovering to overcome 
these problems to help mesenchymal stem cell supply. 
EFFECTS OF DONOR STEM CELL AGE ON CELL 
REPLICATION AND DIFFERENTIATION 
  Human Mesenchymal Stem Cells (hMSCs) are 
clonogenic, proliferate easily and their progenies show a 
broad multilineage differentiation potential. 
1. In Vitro Studies 
  Generally MSCs in the bone marrow are arrested in the 
G0 state, but when these cells are plated in vitro, MSCs exit 
their quiescent state and proliferate to form individual colony 
forming unit-fibroblasts (CFU-Fs). Each of these colonies 
are derived from a single MSC. 
  The number of MSCs in the bone marrow has been 
shown to vary with donor age. But on the other hand there 
are several studies which also did not detect a difference in 
the number of MSCs with varying age [1]. 
 D'Ippolito  et al. studied the effects of MSCs which were 
taken from the vertebral bodies of donors [2]. These were 
then grown in various cultures until they formed colonies 
which were then plated and promoted to cause osteoblastic 
differentiation. The cultures were analyzed and the cells with 
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osteogenic potential were looked at. Closer analysis revealed 
that a higher number of MSCs with osteoblastic potential are 
present in the younger donor cells in comparison to the older 
donor cells. This decrease in the potential to differentiate 
into osteoblasts may partly explain the increased risk of 
osteoporosis in the older population. 
  The progenitor cell numbers and the clonogenic potential 
was compared in donor cells from females under 35 years of 
age with the donor cells of females at the age of 45 and over 
[3]. The results showed that the cellular yield is significantly 
different between the two age groups. Even though both 
groups had the ability to produce colonies, the younger 
donor cells demonstrated a doubling in the potential to clone 
in comparison to the older donor stem cells. In this study 
specific MSC markers were also analysed using flow 
cytometry. The following markers were studied: CD13, 
CD14, CD29, CD34, CD44, CD45, CD49d, CD54, CD71, 
CD90 and CD105 [4,5]. But none of these showed 
significant variations related to the donor age of the MSC. 
  As well as comparing MSC markers, peroxisome 
proliferator-activated receptor gamma (PPAR-) expression 
in undifferentiated and adipogenic differentiated human 
adipocytic stem cells were analyzed by De Girolamo et al. 
[3] and others [6,7]. However, no significant difference in 
PPAR- expression of differentiated human stem cells was 
found between the two age groups in De Girolamo et al's 
study [3]. This therefore suggests that the proliferation and 
differentiation potential between both groups is not affected 
by transcription factors regulating gene expression or by 
MSC markers. 
  However, when the human stem cells were cultured in an 
osteogenic differentiating medium for two weeks, a large 
difference was detected in the alkaline phosphatase (ALP) 
activity. The cells from the younger female donors showed 
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cells had an increase of 40% activity only. From this data it 
is difficult to hypothesize the reasons for the difference seen 
in the osteoblastic differentiation potential even though the 
MSC markers did not show any significant difference. 
  A recent research study by Katsara et al. revealed the 
presence of Dazi, Oct3/4 and Sox2 transcription factors in 
bone marrow-derived MSCs [8]. These are critical for 
embryonic development. But their quantity was shown to be 
significantly lower in younger donor stem cells than in older 
donor stem cells. This therefore may have severe 
implications on the potential of adult stem cells to be used in 
regenerative medicine. 
  We have previously shown that synovial fat pad derived 
MSCs isolated from two groups of five patients with a mean 
age of 57 years (SD 3 years) and 86 years (SD 3 years) 
showed similar proliferation rates and cell surface epitope 
profile [9]. The cells from both groups cultured in osteogenic 
medium exhibited osteogenesis as shown by a significant 
upregulation of alkaline phosphatase and osteocalcin genes, 
and significantly greater alkaline phosphatase enzyme 
activity compared to cells cultured in the control medium. 
The cells cultured in the osteogenic medium also showed 
greater calcium phosphate deposition on alizarin red 
staining. There was no significant difference between the 
osteogenic potential of the two age groups for any of the 
parameters looked at. We concluded that the synovial fat pad 
is a source of stem cells that exhibits osteogenic 
differentiation potential not affected by ageing in later life. 
2. In Vivo Studies 
  Even though hMSCs are being studied for several 
decades, it is only recently that in vivo characteristics of 
MSCs are considered and outlined. Therefore the number of 
studies done in vivo is limited. However, several researchers 
have tried to mimic in vivo properties in order to present the 
nature of the progenitors as would happen in the human 
body. 
  A study by Stolzing et al. looked at the action of hMSCs 
in vivo [10].  They detected a decrease in stem cell 
proliferation with increasing age. This is consistent with the 
finding of an enhancement in the p53 expression and its 
targets p21 and BAX. These factors are known to have 
apoptotic actions which explains the results of this study. 
Similarly, a decrease in the potential to differentiate into 
osteoblasts was detected. 
  Osteoprogenitors in the human bone marrow demonstrate 
the ability to regenerate bone and stroma [11]. These hMSCs 
express a high number of CD146 adhesion molecules. 
Following transplantation of CD146 positive stromal cells, 
they associate with developing sinusoids and eventually 
regenerate human cells in vivo. 
  Recent research with hMSC transplantation into 
cyclosporine-immunosupressed rats after myocardial 
infarction has shown that hMSCs from donors aged 1-5 
years old in comparison to donors aged 50-70 years old, the 
young hMSCs offer the best preserved ejection fraction, 
fractional shortening, left ventricular end-diastolic and end 
systolic tidal volume despite the fact that morphologically 
the hMSCs were similar regardless of age [12]. This research 
was based on suggestions from previous studies that donor 
stem cell age had important impact on the regenerative 
capacity of stem cell therapies. 
  Furthermore, it has been estimated that the population 
doubling of cells from older donors is about twenty five 
percent lower compared with cells from younger individuals 
[13]. With ageing, the ability of isolated MSCs to form 
adherent colonies declines with age. There is a reduction in 
MSCs numbers as the age of the donor cells increase [14]. 
The Problem of Senescence in In Vitro Culturing 
  The unlimited self-renewal ability of MSCs is a major 
feature. This gives stem cells the ability to potentially 
differentiate into any type of cell. They only reach 
senescence as a cellular response when there is extensive 
DNA damage which is irreparable. Therefore, it has a role 
that acts similar to a tumour suppressor. It is an important 
factor of in vitro studies as it may affect the results due to 
replicative and stress senescence. It may also have an impact 
on clinical medicine as MSCs are generally expanded in 
culture in vitro and then they are introduced in vivo to allow 
proceeding with its regenerative purpose. 
  There is a theory which states that the proliferative 
capacity of hMSCs in vitro is considered to be finite; this is a 
concept which is known as the “Hayflick limit” [15]. In 
culture the “Hayflick limit” has been widely cited in papers, 
stemming from Leonard Hayflick he found that replicative 
senescence occurs in vitro. In vitro cultured cells proliferate 
until a limited number of differentiation has occured. Then 
these hMSCs enter a state which is referred to as 'premature 
growth arrest'. This can also be termed as senescence – a 
state where cells are non-responsive to mitogenic stimuli 
even though they are metabolically active. This is explained 
by the suggestion that senescence acts a biological protection 
from neoplastic transformations [16]. 
 Roura  et al. studied the effect of ageing on the 
pluripotential capacity of human CD105+ MSCs as it was 
unclear whether aging modifies MSCs properties [4]. Cells 
of young and elderly donors were obtained. The 
pluripotential capacity was analysed using various induction 
media. The results indicated no significant differences in 
telemere length and lipofuscin accumulation. Both, young 
and older donor-derived cells, showed an increase in the 
number of connexin-43 without any significant difference. 
This therefore does not support the presence of senescence in 
vitro. But on the other hand there are several studies which 
do provide evidence supporting the “Hayflick limit” theory 
as outlined below. 
  Micro-Ribonucleic Acids (miRNAs) are a class of non 
coding silencing RNAs and a single miRNA can regulate up 
to several hundred miRNA targets and as such can have a 
large influence in the cell [17]. It has been shown that miR-
17, miR-19b, miR-20a and miR-106a are downregulated in 
hMSCs with age and may contribute to senescence [18]. 
  The expression of senescence associated beta-
galactosidase is a lysosomal marker of cell senescence in 
vitro [19]. Forkhead box-M1 (FoxM1) is a transcription 
factor that is expressed in proliferating cells. This therefore 
suggests that it may have a role in the regulation of cell 
division. In fact, its activity starts when a cell enters the S 
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which FoxM1 is deleted show signs of difficulty in 
proliferation and exhibit abnormalities. 
  Interestingly a study from bone-marrow derived MSCs 
showed that gene ontology categories relating to DNA 
repair, mitosis, transcriptional regulation and nucleus were 
age-repressed in MSCs, whereas genes involved in 
categories for differentiation, plasma membrane and extra 
cellular matrix were age induced in MSCs [20]. It has been 
highlighted that age associated changes differ a lot between 
cell types; e.g. Haemopoetic Progenitor Cells (HPCs) and 
MSCs do not have the same age-induced gene expression. 
Fascinatingly, Hutchinson-Gilford progeria syndrome, a 
severe autosomal dominant premature ageing condition, is 
linked to a mutation of LMNA gene. Lamin A and Lamin C 
are derived from alternative splicing of LMNA. Lamin A/C 
is crucial for nuclear integrity. In HPCs, lamin A is an age 
induced gene which is also mutated in Hutchinson-Gilford 
progeria. In aged induced gene expression of MSCs 
mesenchyme homeobox (MEOX2) is a negative regulator of 
proliferation in several mesodermal tissues and is affected in 
fibroblasts of patients with Hutchison-Gilford Progeria 
syndrome [21]. Other upregulated genes in MSCs were 
SHOX2 (short stature homeobox 2) and HOXC6 part of the 
developmental regulatory system. Age-repressed homeobox 
genes included HOXA5, HOXB3, HOXB7 and PITX2 
(paired-like homeodomain transcription factor 2) [22]. 
Tactics to Combat Replicative Senescence In Vitro 
  It has been shown that hMSCs enhance proliferation 
capacity when cultured at conditions of low atmospheric 
oxygen. Human MSCs from cancellous bone cultured in 
oxygen tension of 3% showed the rates of cell death and 
hypoxia induced gene transcription were unchanged, but in 
vitro proliferation life span was increased with about 10 
additional population doublings before reaching terminal 
growth arrest [23]. Similarly, whole genome expression 
profiles of primary MSCs from infants and adults have also 
been compared after a short period of atmospheric conditions 
of high and low oxygen tensions. Leptin receptor (LEPR) 
gene expression was increased in MSCs from aged donors in 
aged cells and in those cultivated at elevated oxygen levels. 
Dying MSCs expressed enhanced levels of LEPR. This fits 
in line with low oxygen tension culturing being beneficial. 
Furthermore, LEPR mRNA levels could be used as a 
measure of stem cell ageing to help find more tactics to beat 
stem cell senescence [24]. 
  Cell density in culture has an impact on replicative 
sensensce. Colter et al. [25] showed that hMSCs propagate 
much more rapidly if they are plated at low densities of 1.5 
or 3.0 cells/cm
2. They showed that single cell derived MSC 
clones could be expanded up to 50 PDs in about 10 weeks if 
cultured by repeat passages at low density whereas cells 
stopped growing after 15 passages at high cell density. 
 Simonson  et al. [26] showed that when hMSCs were 
transduced by a retroviral vector containing a gene for the 
catalytic subunit of human telomerase, hTERT, these cells 
underwent more than 260 population doublings. However, 
control cells underwent senescence associated proliferation 
arrest at 26 population doublings. These cells also 
maintained their osteogenic potential. 
  Furthermore, a study that introduced Wild type p53 
Inducibile Phosphatase 1 (Wip1), showed that, it lowered 
p16INKa expression and led to p38 MAPK inactivation in 
hMSCs and successfully delayed cell growth arrest of these 
cells in prolonged culture. P16INK4a is a known tumour 
suppressor that inhibits G1 cyclin dependent kinase (CDK) 
function, leading to the activation of the retinoblastoma 
protein (Rb), eventually leading to premature growth arrest. 
Interestingly, Wip1 failed to induce re-entry of post 
senescent hMSCs into the cell cycle. Suggesting induction of 
p16 and Rb activation may be an important step in the 
process of irreversible senescence in hMSCs [27]. 
Furthermore, it has been shown low dose ionising radiation 
from rat bone marrow MSCs at 50 and 75mGY encouraged 
the proliferation of rat MSCs via  MAPK/ERK signalling 
pathway activation [28]. 
  When looking at the medium the cells are grown in, 
fibroblast growth factors are found to be a family of heparin 
binding polypeptide growth factors that are known to 
regulate cell proliferation and differentiation. In addition, the 
proliferation of human MSCs from bone marrow with FGF-2 
culture medium supplementation was superior to population 
doubling-matched controls [29]. FGF-2 has been 
demonstrated in a dose dependant manner to stimulate the 
proliferation of mesenchyme derived progenitor cells 
cultures derived from adult bone. Although cells from older 
bones were less responsive to FGF-2 than those from 
younger bones, this is still a potential valuable factor in MSC 
culture [30]. Furthermore, the culturing of MSCs in human 
platelet lysate instead of fetal bovine serum resulted in a 
higher number of cell divisions [31]. 
CONCLUSION 
  The evidence on whether mesenchymal stem cell number 
in vivo is affected by donor age is inconclusive. Considering 
that older individuals have more fat in their bones, could 
studies have detected a difference by picking up on this 
artefact? The mesenchymal stem cell is an elusive cell. To 
this day we are unable to fully identify it, often we know 
within a group of cells from bone marrow there is a stem cell 
amongst the group. This surely presents challenges in 
quantification. The concept of replicative senescence poses 
wide ranging questions. Since stem cells should not really 
senesce are we highlighting these are not true stem cells? 
Considering in the past, research on mesenchymal stem cells 
bypassed legislation that was applicable to embryonic stem 
cells and this added to their attractiveness in research; 
whereas nowadays, they are subject to rigorous tests. Should 
we really be aiming for research with embryonic stem cells 
and avoiding the replicative senescence issue? By trying to 
combat replicative senescence are we in danger of leading to 
neoplastic transformations? This needs to be researched into 
and could have safety implications. Mesenchymal stem cells 
present an attractive option for treating an elderly generation 
from their own bone marrow, but many more studies are 
needed. 
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